Joachim Boldt (medical doctor)

from Wikipedia, the free encyclopedia

Joachim Boldt (born September 29, 1954 ) is a German anesthesiologist . He was considered one of the leading researchers in the field of colloidal infusion solutions until he was convicted of scientific fraud through data falsification and disregard of ethical standards. On November 26, 2010, Boldt lost his position as chief physician for anesthesiology and intensive care medicine at the Ludwigshafen Clinic . He resigned from the German Society for Anaesthesiology and Intensive Care Medicine . His unscheduled professorship was withdrawn from the Justus Liebig University in Giessen .

Live and act

Joachim Boldt first studied chemistry from 1974 to 1975 at the Ruhr University in Bochum . In 1975 he changed the subject and the university and studied medicine at the Philipps University of Marburg until 1980 . He completed his practical year (PJ) in 1981/1982 at the Evangelical Jung-Stilling Hospital in Siegen , where he then began his further training in the anesthesia department. In 1982 he received his doctorate from the Philipps University of Marburg . He moved in the same year as a further training assistant at the Department of Anesthesia and Intensive Care Medicine, University of Giessen, where in 1987 the training as a specialist of Anesthesiology and Intensive Care Medicine graduated and at the University habilitated .

He then continued to work as a university assistant in Giessen and was appointed private lecturer in 1990 . In 1993 the University of Giessen awarded him the title of adjunct professor. On January 1, 1996, Joachim Boldt moved to the city of Ludwigshafen am Rhein as chief physician and director of the clinic for anesthesiology and surgical intensive care medicine . In 2009 he was president of the German Anesthesia Congress (DAC) in Leipzig . He worked in Ludwigshafen until November 26, 2010. Due to a science scandal, his position as chief physician was withdrawn and in February 2011 the University of Giessen revoked the title of professor for inactivity in teaching.

Science scandal

As early as 2005, the public prosecutor in Giessen had investigated Boldt and colleagues for data manipulation and illegal studies on people with hydroxyethyl starch (HES). The case made headlines nationwide after a publication in the Gießener Allgemeine Zeitung . However, the allegations could not be substantiated.

Boldt had published around 70 specialist articles on hydroxyethyl starch, mostly with positive evaluations of the drug. This corresponds to 0.68% of the total literature on HES.

On October 28, 2010, the editor of the journal Anesthesia & Analgesia withdrew a publication by Joachim Boldt that had been published in 2009. After doubts about the accuracy of the data, a scientific commission came to the conclusion that there was no convincing evidence that the study on which the publication was based had been carried out.

The editors of 16 international journals withdrew numerous other publications by Boldt after an analysis by the State Medical Association of Rhineland-Palatinate had shown that 89 of a total of 102 studies had not been approved by the ethics committees . The Association of Surgeons of Great Britain and Ireland therefore wants to review its guidelines, as six of a total of 142 footnotes in the Guidelines on Intravenous Fluid Therapy for Adult Surgical Patients (GIFTASUP) refer to work by Boldt. However, the Presidium of the German Society for Anesthesiology and Intensive Care Medicine stated in a statement on February 21, 2011 that “the clinical use of HES does not currently have to be reassessed”, since Boldt is neither involved in approval studies nor in examinations in emergency and medical care Intensive care medicine would have been involved.

The German Medical Association has withdrawn Section 5 of the current cross-sectional guidelines on therapy with blood components and plasma derivatives on therapy recommendations with human albumin , which Boldt had written, for revision.

14 publications were removed from the AWMF-S3 guideline on the intensive care of cardiac surgery patients - hemodynamic monitoring and cardiovascular therapy after the Rhineland-Palatinate State Medical Association announced after an analysis that 89 of a total of 102 studies by Boldt's group of authors had none Has received approval from the ethics committees.

Based on recent studies on the risk-benefit ratio of the recommended Pharmacovigilance Committee for Risk Assessment (Pharmacovigilance Risk Assessment Committee, PRAC) of the European Medicines Agency (European Medicines Agency) even include the withdrawal of marketing approval for products that hydroxyethyl starch on June 14, 2013.

The Joachim Boldt affair attracted a great deal of international attention and was also described as the biggest science scandal since the Wakefield case . An independent investigative commission confirmed the serious allegations in its final report published on August 8, 2012.

As a further consequence of the “Boldt Complex”, the Justus Liebig University of Gießen withdrew the doctoral degree in two cases in January 2013. In a communication from the university it was stated: “Both the former Boldt doctoral student P. and the doctor T. concerned, the doctoral committee assumes after a detailed examination that the principles for safeguarding good scientific practice have been violated and deceived. “By judgment of October 15, 2013 (AZ 3 K 1293/12) the Administrative Court of Gießen lifted the revocation of the doctorate in the case of doctor T. However, the judgment is not yet final.

Fonts (selection)

Individual evidence

  1. ↑ a b press kit ( memento from March 19, 2012 in the Internet Archive ) for the 126th Congress of the German Society for Surgery 2009 in Munich
  2. ↑ Jürgen Schüttler: Freedom and responsibility in science - two sides of the same coin. Anästh Intensivmed 52 (2011): 170-171, online ( Memento from March 4, 2011 in the Internet Archive ) (PDF document; 386 kB)
  3. ↑ a b Veronika Hackenbroch: Too good to be true. Spiegel Online from November 29, 2010, online
  4. ↑ Press release of the Justus Liebig University Giessen from February 15, 2011
  5. ↑ Fake studies: Joachim Boldt could lose his professorial title. Gießener Allgemeine Zeitung from January 12, 2011.
  6. ↑ a b Does the clinical use of modern hydroxyethyl starch solutions need to be reassessed at present? Statement by the DGAI Presidium of February 21, 2011. Anästh Intensivmed 52 (2011), 172-173, online ( Memento of March 4, 2011 in the Internet Archive ) (PDF document; 386 kB)
  7. ↑ J. Boldt et al .: Cardiopulmonary Bypass Priming Using a High Dose of a Balanced Hydroxyethyl Starch Versus an Albumin-Based Priming Strategy. Anesthesia & Analgesia 109: 1752-1762 (2009)
  8. ^ Information Service Science: DGAI: Scientific misconduct in anesthesia unacceptable from November 26, 2010
  9. ↑ Statement of the editors (PDF document; 139 kB)
  10. ↑ Retraction Watch on March 2, 2011
  11. ↑ Open letter ( memento of July 20, 2012 in the web archive archive.today ) of the Association of Surgeons of Great Britain and Ireland
  12. ^ Boldt affair: guidelines put to the test. Deutsches Ärzteblatt from March 7, 2011, online
  13. ↑ Cross-sectional guidelines (BÄK) on therapy with blood components and plasma derivatives - 4th edition 2008 ( Memento from July 13, 2012 in the web archive archive.today ) - published by the German Medical Association on the recommendation of its Scientific Advisory Board
  14. ↑ Scientific Advisory Board: Cross-Sectional Guidelines for Therapy with Blood Components and Plasma Derivatives - Suspension of Chapter 5 Human Albumin Dtsch Arztebl 2011; 108 (1-2): A-58 / B-46 / C-46
  15. ↑ Veronika Hackenbroch: Scientific vacuum. Spiegel Online from January 3, 2011, online
  16. ↑ Statement for the AWMF website on the revised version of the S3 guideline on intensive care for cardiac surgery patients - hemodynamic monitoring and cardiovascular therapy. ( Memento from March 19, 2016 in the Internet Archive ) (PDF; 82 kB)
  17. ↑ Pharmacovigilance Committee for Risk Assessment (Pharmacovigilance Risk Assessment Committee, PRAC) of the European Medicines Agency (European Medicines Agency) PRAC recommends suspending marketing Authorizations for infusion solutions Containing hydroxyethyl starch. June 14, 2013, press release , PDF (71 kB)
  18. ↑ Heidi Blake, Holly Watt, Robert Winnett: Millions of surgery patients at risk in drug research fraud scandal . The Telegraph of March 3, 2011
  19. ↑ 'Unethical' anaesthetics research is retracted. BBC News Health March 4, 2011
  20. ^ Mahlon M. Wilkes, Roberta J. Navickis: The Boldt Affair: A Quandary for Meta-Analysts. Anaesthesiology News 39 (2013), online
  21. ↑ "Anesthetist manipulated studies for years" Deutsches Ärzteblatt August 8, 2012
  22. ↑ uni-giessen.de of January 17, 2013: Further consequences in the “Boldt complex”: JLU withdraws doctoral degrees in two cases. Former doctoral students P. and T. have deceived in their dissertations in the opinion of the doctoral committee.
  23. ↑ Press release of the Administrative Court Gießen from October 15, 2013
personal data
SURNAME Boldt, Joachim
BRIEF DESCRIPTION German anesthesiologist
DATE OF BIRTH September 29, 1954